| scholarly article | Q13442814 |
| P50 | author | Olivier Hermine | Q28322530 |
| Nicolas Pallet | Q38799615 | ||
| Julien Zuber | Q42859640 | ||
| Renaud Snanoudj | Q51808922 | ||
| P2093 | author name string | F Martinez | |
| C Legendre | |||
| D Anglicheau | |||
| M Rabant | |||
| R Sberro-Soussan | |||
| E Thervet | |||
| A Loupy | |||
| M Leruez | |||
| D Nochy | |||
| C Suberbielle-Boissel | |||
| S Candon | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| desensitization | Q2700499 | ||
| P304 | page(s) | 681-686 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies | |
| P478 | volume | 10 |
| Q39630785 | 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody |
| Q47292306 | A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection |
| Q41118002 | Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management |
| Q38215262 | Acute and chronic antibody-mediated rejection in pediatric kidney transplantation |
| Q35586614 | Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q90730885 | Antibody-Mediated Rejection Treatment With Bortezomib in Renal Transplant Recipients: A Single-Center 24-Month Follow-up Case Report |
| Q37990988 | Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale |
| Q39366396 | Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies |
| Q35915453 | Antibody-mediated rejection in kidney transplantation: a review |
| Q37835834 | Antibody-mediated rejection in kidney transplantation: an update |
| Q42553965 | Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes |
| Q37782255 | B cells and transplantation tolerance |
| Q53308226 | Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series. |
| Q50996014 | Bortezomib in ABO-incompatible kidney transplant desensitization: a case report. |
| Q34189435 | Bortezomib in kidney transplantation |
| Q33415926 | Bortezomib use in a pediatric cardiac transplant center |
| Q42913151 | Bortezomib: a new player in pre- and post-transplant desensitization? |
| Q38035660 | Chronic renal allograft injury: early detection, accurate diagnosis and management. |
| Q37931981 | Clinical and investigational use of proteasome inhibitors for transplant rejection |
| Q52881666 | Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation. |
| Q39716270 | Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. |
| Q37834028 | Current immunosuppressive treatment after kidney transplantation |
| Q26829789 | Current state of renal transplant immunosuppression: Present and future |
| Q38874937 | Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting |
| Q46402292 | Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen |
| Q37960177 | Emerging drugs for the treatment of transplant rejection |
| Q37833481 | End-stage renal disease in 2010: Innovative approaches to improve outcomes in transplantation |
| Q50852390 | Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient. |
| Q37964270 | Histology and proteinuria after renal transplantation |
| Q36612789 | Human leukocyte antigen antibody incompatible renal transplantation |
| Q38945149 | Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients |
| Q37778273 | Immunosuppression in the sensitized heart transplant recipient |
| Q37375622 | Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation |
| Q36901669 | Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients |
| Q53782591 | Living-donor kidney transplantation with existing anti-donor specific antibodies at a Japanese single center. |
| Q37361071 | Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study. |
| Q27010224 | Modern approaches to incompatible kidney transplantation |
| Q37898509 | New therapeutic approaches to antibody-mediated rejection in renal transplantation |
| Q38176005 | Novel immunosuppressive agents in kidney transplantation |
| Q30544649 | Pros and cons for C4d as a biomarker |
| Q83426716 | Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation |
| Q26830410 | Proteasome inhibitor-based therapy for antibody-mediated rejection |
| Q27011485 | Proteasome inhibitors in progressive renal diseases |
| Q38674466 | Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation |
| Q37313051 | Report from a consensus conference on antibody-mediated rejection in heart transplantation |
| Q37888770 | Targeting B cells and antibody in transplantation |
| Q38068534 | Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? |
| Q50950214 | The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates. |
| Q40745610 | Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients |
| Q27021397 | Treatment options and strategies for antibody mediated rejection after renal transplantation |
| Q46908752 | Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a single-center experience |
Search more.